Joseph S. Payne
Lawyers

Filters
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
loanDepot $600 million senior notes offering
We advised the initial purchasers on the high-yield debt offering
loanDepot $62 million IPO
The shares are listed on the New York Stock Exchange
Precigen $129 million common stock offering
We advised the underwriters in connection with the SEC-registered equity offering
HumanCo Acquisition $287.5 million IPO
Davis Polk advised the underwriter in connection with the initial public offering of 28,750,000 units of HumanCo Acquisition Corp., including 3,750,000 units purchased pursuant to the…
Bristol Myers Squibb $7 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol-Myers Squibb Company,…
loanDepot $500 million senior notes offering
Davis Polk advised the representative of the initial purchasers in connection with the debut Rule 144A/Regulation S offering by LD Holdings Group LLC of $500 million aggregate principal…
Freeline Therapeutics Holdings $158.8 million IPO
Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…
Silicon Laboratories $535 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Silicon Laboratories Inc. of $535 million aggregate principal amount of its…
Freeport-McMoRan $1.3 billion notes offering
Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.3 billion of senior notes. The offering consisted of two tranches of senior notes,…